Related references
Note: Only part of the references are listed.Azacitidine in untreated acute myeloid leukemia: A report on 149 patients
Sylvain Thepot et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
Lisa Pleyer et al.
ANNALS OF HEMATOLOGY (2014)
BH3 mimetics and multi-kinase inhibition in AML
Elspeth M. Beauchamp et al.
BLOOD (2012)
A novel hierarchical prognostic model of AML solely based on molecular mutations
Vera Grossmann et al.
BLOOD (2012)
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML
Alan K. Burnett et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial
Giovanna Cannas et al.
LEUKEMIA & LYMPHOMA (2012)
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
Erdogan Taskesen et al.
BLOOD (2011)
ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
Klaus H. Metzeler et al.
BLOOD (2011)
The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome
A. K. Burnett et al.
LEUKEMIA (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly Patients at High Risk for Anthracycline Toxicity
Edward Agura et al.
ONCOLOGIST (2011)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Amanda F. Cashen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
DNMT3A Mutations in Acute Myeloid Leukemia.
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
Jean-Luc Harousseau et al.
BLOOD (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Mutation in TET2 in Myeloid Cancers
Francois Delhommeau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-tine therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
Stefan Faderl et al.
BLOOD (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes
Sabine Knipp et al.
CANCER (2007)
G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent
R. Tonelli et al.
LEUKEMIA (2006)
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
S Faderl et al.
BLOOD (2006)
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome - Predictive prognostic models for outcome
H Kantarjian et al.
CANCER (2006)
5-aza-cytidine is a potent inhibitor of DNA methyltransferase 3a and induces apoptosis in HCT-116 colon cancer cells via Gadd45-and p53-dependent mechanisms
R Schneider-Stock et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Trends in the treatment of acute myeloid leukaemia in the elderly
K Lang et al.
DRUGS & AGING (2005)
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study
JE Anderson et al.
BLOOD (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
